| Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ... The lancet oncology 17 (11), 1590-1598, 2016 | 736 | 2016 |
| Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. P Sharma, P Bono, JW Kim, P Spiliopoulou, E Calvo, RN Pillai, PA Ott, ... Journal of Clinical Oncology 34 (15_suppl), 4501-4501, 2016 | 62 | 2016 |
| Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real‐life experience K Rust, P Spiliopoulou, CY Tang, C Bell, D Stirling, THF Phang, ... BJOG: An International Journal of Obstetrics & Gynaecology 125 (11), 1451-1458, 2018 | 40 | 2018 |
| NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer EYL Leung, DP Ennis, PR Kennedy, C Hansell, S Dowson, ... Molecular Therapy-Oncolytics 16, 289-301, 2020 | 39 | 2020 |
| A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer IR Macpherson, P Spiliopoulou, S Rafii, M Saggese, RD Baird, ... Breast Cancer Research 22, 1-9, 2020 | 27 | 2020 |
| Dual G9A/EZH2 inhibition stimulates antitumor immune response in ovarian high-grade serous carcinoma P Spiliopoulou, S Spear, H Mirza, I Garner, L McGarry, F Grundland-Freile, ... Molecular cancer therapeutics 21 (4), 522-534, 2022 | 25 | 2022 |
| Virotherapy: cancer gene therapy at last? AE Bilsland, P Spiliopoulou, TRJ Evans F1000Research 5, 2016 | 24 | 2016 |
| All is not lost: learning from 9p21 loss in cancer P Spiliopoulou, SYC Yang, JP Bruce, BX Wang, HK Berman, TJ Pugh, ... Trends in Immunology 43 (5), 379-390, 2022 | 18 | 2022 |
| Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer CR Lindsay, P Spiliopoulou, A Waterston Therapeutic Advances in Medical Oncology 7 (2), 107-121, 2015 | 17 | 2015 |
| Metronomic oral cyclophosphamide in relapsed ovarian cancer P Spiliopoulou, S Hinsley, IA McNeish, P Roxburgh, R Glasspool International Journal of Gynecologic Cancer 31 (7), 2021 | 11 | 2021 |
| Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study. P Sharma, MK Callahan, P Bono, JW Kim, P Spiliopoulou, E Calvo, ... Journal of Clinical Oncology 36 (6_suppl), 414-414, 2018 | 10 | 2018 |
| A pilot study of subjective well-being in colorectal cancer patients and their caregivers J Graham, P Spiliopoulou, R Arbuckle, JA Bridge, J Cassidy Patient related outcome measures, 111-119, 2017 | 9 | 2017 |
| Circulating biomarkers for therapeutic monitoring of anti-cancer agents HJ Janse van Rensburg, P Spiliopoulou, LL Siu The Oncologist 27 (5), 352-362, 2022 | 8 | 2022 |
| Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers P Spiliopoulou, O Vornicova, S Genta, A Spreafico International Journal of Molecular Sciences 24 (2), 1294, 2023 | 7 | 2023 |
| Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy P Spiliopoulou, HJ Janse van Rensburg, L Avery, V Kulasingam, A Razak, ... Cell Death & Disease 14 (1), 49, 2023 | 6 | 2023 |
| Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208. P Spiliopoulou, A Kasi, LI Abushahin, DB Cardin, HJ Lenz, F Dayyani, ... Journal of Clinical Oncology 40 (16_suppl), 4136-4136, 2022 | 6 | 2022 |
| First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety … AM Di Giacomo, F Santangelo, G Amato, E Simonetti, J Graham, ... Journal of Clinical Oncology 40 (16_suppl), 3107-3107, 2022 | 6 | 2022 |
| Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma. S Genta, DV Araujo, S Keshavarzi, T Pimentel Muniz, Z Saeed Kamil, ... Journal of Clinical Oncology 40 (16_suppl), 9579-9579, 2022 | 6 | 2022 |
| FIESTA: A phase Ib and pharmacokinetic trial of AZD4547 in combination with gemcitabine and cisplatin. RH Jones, DA Anthoney, RJ Jones, SJ Crabb, SA Hussain, AJ Birtle, ... Journal of Clinical Oncology 34 (15_suppl), 4521-4521, 2016 | 6 | 2016 |
| A Case of Lenvatinib‐Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer K Fleming, J McGuinness, D Kipgen, H Glen, P Spiliopoulou Case Reports in Oncological Medicine 2018 (1), 6927639, 2018 | 5 | 2018 |
